Financials in USD. Standardized financial statements.
A compact view of how CymaBay Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $31.07M | $0 | $0 | $0 | $0 | $0 | $10.00M | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $681,000 | $710,000 | $688,000 | $632,000 | $800,000 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $30.39M | -$710,000 | -$688,000 | -$632,000 | -$800,000 | $0 | $10.00M | $0 | $0 | $0 |
| Gross Margin? | +97.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +100.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $132.07M | $93.11M | $87.58M | $53.31M | $103.08M | $72.50M | $31.32M | $25.59M | $25.90M | $24.01M |
| Operating Income? | -$101.68M | -$93.11M | -$87.58M | -$52.60M | -$108.15M | -$72.50M | -$21.32M | -$25.59M | -$25.90M | -$24.01M |
| EBITDA? | -$85.74M | -$92.40M | -$86.73M | -$50.35M | -$108.15M | -$71.70M | -$26.44M | -$25.30M | -$14.59M | -$24.01M |
| Income Before Tax | -$105.37M | -$106.00M | -$90.00M | -$50.99M | -$102.81M | -$72.55M | -$27.56M | -$26.67M | -$15.53M | -$31.92M |
| Income Tax Expense | $0 | $12.89M | $2.58M | -$2.32M | -$572,000 | $293,000 | $0 | $0 | $0 | $0 |
| Net Income? | -$105.37M | -$118.89M | -$92.58M | -$48.66M | -$102.24M | -$72.55M | -$27.56M | -$26.67M | -$15.53M | -$31.92M |
| EPS? | $-0.99 | $-1.35 | $-1.30 | $-0.71 | $-1.53 | $-1.25 | $-0.79 | $-1.14 | $-0.82 | $-2.65 |
| Diluted EPS? | $-0.99 | $-1.35 | $-1.30 | $-0.71 | $-1.53 | $-1.25 | $-0.79 | $-1.14 | $-0.82 | $-2.65 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality